Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

The Eli Lilly-backed antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

University of Florida has backed a second round for Atsena, a vision loss therapy developer exploiting inventions the institution had originally licensed to Sanofi.

Junshi Biosciences has invested in the University of Birmingham-founded cancer immunotherapy developer, building on a research collaboration deal.

Pfizer Ventures-backed cancer drug developer BioAtla's shares popped on its first day of trading yesterday following a $189m initial public offering.

Blue Venture Fund returned as part of the latest funding to be raised by the mobile substance abuse treatment service.

The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies.

Mayo Clinic had invested in and partnered the medical data software provider before joining a series C round also featuring NTTVC.

The European Commission-backed venture fund has secured commitments from Nestlé, Volkswohl Bund Versicherungen and Neste for its second close.